Few research peptides have drawn as much preclinical attention as BPC-157. The name stands for “Body Protection Compound-157,” and the molecule is a synthetic 15-amino-acid peptide that derives from a protein in gastric juice. Across a large body of animal research, scientists have studied it for its effects on blood-vessel formation and tissue repair. As a result, it now ranks among the most-cited entries in the research peptide literature. This profile reviews what BPC-157 is, how studies describe its mechanism, and — just as importantly — where the evidence currently stands.
What Is BPC-157?
BPC-157 is a pentadecapeptide — a chain of 15 amino acids — with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). It matches a partial sequence of “Body Protection Compound,” a protein that researchers first isolated from human gastric juice. Notably, one feature stands out: the run of three consecutive proline residues near the N-terminus, which helps explain the peptide’s stability. Kimera supplies BPC-157 for laboratory research in lyophilized, liquid, and capsule formats.
How BPC-157 Works in Preclinical Models
Unlike peptides that act on a single, well-defined receptor, BPC-157 seems to work through several overlapping pathways. By far the most documented is angiogenesis — the growth of new blood vessels.
Angiogenesis and VEGF
First, studies report that BPC-157 raises vascular endothelial growth factor (VEGF) and engages the VEGFR2 receptor, which together shape new vessel formation at injury sites (Brcic et al., 2009). Interestingly, that same work found no direct angiogenic effect in isolated cell cultures, yet it showed clear angiogenic modulation in living tissue. In other words, the effect seems to depend on the healing environment rather than on endothelial cells alone.
The Nitric Oxide System and Growth Factors
Second, a recurring theme involves the nitric oxide (NO) system. Researchers describe BPC-157 interacting with NO synthesis through the Akt-eNOS axis, which in turn influences vascular tone and the tissue’s response to injury. In addition, several studies report that the peptide raises growth factors — most notably, it increased growth hormone receptor expression in cultured tendon fibroblasts (Chang et al., 2018). Taken together, these pathways are how the literature explains the peptide’s effects on connective tissue in animal models.
A Peptide That Survives the Stomach
Most peptides are fragile. They break down quickly in acidic or enzyme-rich conditions. BPC-157, however, behaves differently. The literature describes it as unusually stable, and it resists hydrolysis even in gastric juice. Because of that toughness, it drew research attention early on — and researchers still cite the property when they design administration protocols for animal studies.
What the Research Shows
Scientists have tested BPC-157 across a wide range of rodent injury models. In those preclinical studies, the peptide sped the healing of tendon, ligament, muscle, bone, skin, and gut tissue. Moreover, the same studies noted fewer inflammatory markers and better microvascular integrity. Throughout this work, one mechanistic thread recurs: modulated angiogenesis and growth-factor signaling, rather than a single targeted action. Still, every one of these results comes from animal or cell-culture work — a point the next section makes central.
Where the Evidence Stands
Now for the essential context. The BPC-157 literature is largely preclinical — rodent models and cell cultures dominate it. In humans, only small pilot studies exist, and the peptide holds no regulatory approval for human use. Indeed, reviews of the field openly weigh its regenerative signal against the absence of large, controlled human trials (narrative review, 2025). For researchers, then, BPC-157 reads best as a compound of active preclinical investigation — not as a validated therapeutic.
Sourcing and COA Verification
For any research peptide, identity and purity decide whether the results mean anything. After all, a peptide that carries truncated or mis-synthesized sequences can quietly derail an experiment. To address that risk, every Kimera lot ships with third-party COA verification — covering both identity confirmation and purity analysis — and we post the results openly in our public COA archive. So before ordering BPC-157, reviewers can check the current COAs first.
Frequently Asked Questions
What is BPC-157?
It is a synthetic 15-amino-acid peptide (sequence GEPPPGKPADDAGLV) that matches a partial sequence of a protein in gastric juice.
What does the research focus on?
Mostly, preclinical studies examine angiogenesis (through VEGF/VEGFR2), nitric oxide signaling, growth-factor upregulation, and tissue repair in animal models.
Is BPC-157 approved for human use?
No. BPC-157 holds no regulatory approval, and Kimera supplies it strictly for laboratory and research use. Furthermore, the published evidence remains largely preclinical.
What is BPC-157’s molecular weight?
BPC-157 has the molecular formula C₆₂H₉₈N₁₆O₂₂ and a molar mass of 1419.55 g/mol (CAS 137525-51-0).
Kimera sells BPC-157 for laboratory and research use only. Not for human consumption, nor for medical, veterinary, or household use.
References
BPC-157, PubChem CID 9941957. https://pubchem.ncbi.nlm.nih.gov/compound/9941957
Brcic L, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009. PMID 20388964. https://pubmed.ncbi.nlm.nih.gov/20388964/
Chang CH, et al. Pentadecapeptide BPC 157 enhances growth hormone receptor expression in tendon fibroblasts. PMC6271067. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6271067/
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. PMC12446177. https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
What is BPC-157’s molecular weight?
BPC-157 has the molecular formula C₆₂H₉₈N₁₆O₂₂ and a molar mass of 1419.55 g/mol (CAS 137525-51-0).
